Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coated aldehyde oxystarch capsules for chronic kidney disease stage 3 and above
ChiCTR2100052024Phase 4Not yet recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Nov 2021
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aldehyde oxystarch in chronic kidney disease (CKD) (4 arms), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoint: Renal function. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
aldehyde oxystarch
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2100052024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052024.